OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing late-stage intratumoural cancer immunotherapies, announced on Tuesday Dr Yuhang Zhao of China Grand Enterprises, Chao Zhou of CGP and Kevin R Smith of Sirtex as its new directors.

Dr Zhao was most recently a member of the Bayer Global Leadership Circle. She established one of Bayer's four Global Clinical Development sites, located in Beijing, China in 2009. She then became head of Global Strategy for Bayer Consumer Health, reporting to the president. Prior to her positions in the pharmaceutical industry, Dr Zhao held positions as a stock analyst at PaineWebber and was a management consultant specialising in strategies for life science companies. Presently, Dr Zhao serves on the board of R2 Technologies and is a senior adviser to China Grand Enterprises.

Chao Zhou is the executive deputy officer of China Grand Pharmaceutical and Healthcare Holdings Limited. Since 2018, he has served on the board of directors of Grand Pharma Sphere Pty Ltd. Prior to his role as executive deputy officer, he served as a management director in the Department of Legal Security for China Grand Enterprises Inc.

Smith is the chief executive officer of Sirtex Medical US Holdings Inc. He has more than 20 years of sales and marketing experience in the medical device industry. Prior to his appointment to CEO, he was executive vice president of Sales & Marketing, Americas. Before joining Sirtex, he was executive vice president of Business Development at Gel-e Inc. His earlier positions include chief commercial officer of Sensium Healthcare along with global vice president of Sales & Marketing at Teleflex, where he was the senior sales and marketing executive in the company's cardiac business unit.